tetano
Editor, Senior Moderator
Eur J Haematol
. 2022 Jul 10.
doi: 10.1111/ejh.13826. Online ahead of print.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
Al-Ola Abdallah[SUP] 1 2 [/SUP], Zahra Mahmoudjafari[SUP] 3 2 [/SUP], Tahani Atieh[SUP] 3 [/SUP], Nausheen Ahmed[SUP] 1 2 [/SUP], Wei Cui[SUP] 3 2 [/SUP], Leyla Shune[SUP] 1 2 [/SUP], Meera Mohan[SUP] 4 2 [/SUP], Joseph McGuirk[SUP] 1 [/SUP], Cassie Remker[SUP] 3 [/SUP], Margaret Foss[SUP] 3 [/SUP], Ellie Karloff[SUP] 3 [/SUP], Heather Fitch[SUP] 3 [/SUP], Shebli Atrash[SUP] 5 2 [/SUP]
Affiliations
Abstract
Many patients with plasma cell disorder (PCD) on active treatment with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospitalization, with an increased mortality rate over healthy adults. The FDA approved two mRNA vaccines against SARS-CoV-2: BNT162b2 & mRNA-1273. To assess the efficacy of vaccination in patients with PCD, retrospectively, we identified all patients on active treatment. A total of 149 patients were included. Neutralizing antibodies (NAbs) levels against SARS-CoV-2 adequate, intermediate and no response were observed in 42%,32% and 26%, respectively. Low NAbs were seen in patients on daratumumab combinations or anti-BCMA therapy, low lymphocytes, and low IgG levels. Twenty-three (15%) patients have SARS CoV-2, while 8% required hospitalization, majority of these patients had intermediate or no response based on NAbs levels.Therefore, checking NAbs may be clinically helpful in identifying patients' responses. Further prospective studies should ascertain the value of a 3[SUP]rd[/SUP] vaccine dose in this population.
Keywords: SARS-CoV-2; mRNA vaccine; multiple myeloma; plasma cell disorder.
. 2022 Jul 10.
doi: 10.1111/ejh.13826. Online ahead of print.
Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
Al-Ola Abdallah[SUP] 1 2 [/SUP], Zahra Mahmoudjafari[SUP] 3 2 [/SUP], Tahani Atieh[SUP] 3 [/SUP], Nausheen Ahmed[SUP] 1 2 [/SUP], Wei Cui[SUP] 3 2 [/SUP], Leyla Shune[SUP] 1 2 [/SUP], Meera Mohan[SUP] 4 2 [/SUP], Joseph McGuirk[SUP] 1 [/SUP], Cassie Remker[SUP] 3 [/SUP], Margaret Foss[SUP] 3 [/SUP], Ellie Karloff[SUP] 3 [/SUP], Heather Fitch[SUP] 3 [/SUP], Shebli Atrash[SUP] 5 2 [/SUP]
Affiliations
- PMID: 35810359
- DOI: 10.1111/ejh.13826
Abstract
Many patients with plasma cell disorder (PCD) on active treatment with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) require hospitalization, with an increased mortality rate over healthy adults. The FDA approved two mRNA vaccines against SARS-CoV-2: BNT162b2 & mRNA-1273. To assess the efficacy of vaccination in patients with PCD, retrospectively, we identified all patients on active treatment. A total of 149 patients were included. Neutralizing antibodies (NAbs) levels against SARS-CoV-2 adequate, intermediate and no response were observed in 42%,32% and 26%, respectively. Low NAbs were seen in patients on daratumumab combinations or anti-BCMA therapy, low lymphocytes, and low IgG levels. Twenty-three (15%) patients have SARS CoV-2, while 8% required hospitalization, majority of these patients had intermediate or no response based on NAbs levels.Therefore, checking NAbs may be clinically helpful in identifying patients' responses. Further prospective studies should ascertain the value of a 3[SUP]rd[/SUP] vaccine dose in this population.
Keywords: SARS-CoV-2; mRNA vaccine; multiple myeloma; plasma cell disorder.